REZOLUTE INC (RZLT)

US76200L3096 - Common Stock

1.345  -0.02 (-1.1%)

REZOLUTE INC

NASDAQ:RZLT (9/28/2023, 7:12:03 PM)

1.345

-0.02 (-1.1%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)09-14 2023-09-14/amc
Earnings (Next)11-07 2023-11-07/amc
Ins Owners0.07%
Inst Owners65.78%
Market Cap49.53M
Shares36.83M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts85.45
IPO12-23 2011-12-23
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RZLT Daily chart

Company Profile

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California. The company went IPO on 2011-12-23. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. The company is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The firm is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.

Company Info

REZOLUTE INC

275 Shoreline Drive, Suite 500

Redwood City CALIFORNIA 94065

P: 16502064507.0

CEO: Nevan Elam

Employees: 42

Website: https://www.rezolutebio.com/

RZLT News

News Image14 days ago - Rezolute, Inc.Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

News Image14 days ago - Rezolute, Inc.Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

News Image23 days ago - Rezolute, Inc.Rezolute to Participate in Upcoming Investor Conferences in September
News Image23 days ago - Rezolute, Inc.Rezolute to Participate in Upcoming Investor Conferences in September

REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to...

News Image3 months ago - Rezolute, Inc.Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
News Image3 months ago - Rezolute, Inc.Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m....

RZLT Twits

Here you can normally see the latest stock twits on RZLT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example